Hepatitis C Detection: Are You Getting the Most Accurate Results?
"A new study reveals how to improve the accuracy of hepatitis C antibody testing, ensuring quicker and more reliable diagnoses."
Hepatitis C virus (HCV) is a major global health concern, affecting millions worldwide. Early and accurate diagnosis is crucial for effective treatment and prevention of liver damage, including cirrhosis and liver cancer. The standard method for detecting HCV infection involves screening for antibodies to the virus (anti-HCV).
Anti-HCV assays are the first step in identifying potential infections. However, these tests can sometimes produce false-positive results, leading to unnecessary anxiety and further testing. Therefore, it's essential to optimize testing strategies to ensure accuracy and efficiency.
This article explores a recent study that evaluated the performance of the anti-HCV VIDAS® test and proposes a refined testing algorithm to improve the reliability of HCV screening. Understanding these advancements can help individuals and healthcare providers make informed decisions about HCV testing.
From Clinical Clues to HCV Tests
The history of hepatitis C unfolded through a sequence of clinical studies that pointed to an infectious agent associated with hepatitis, followed by identification of what became known as HCV and the development of diagnostic tests. The full molecular identification of the virus and demonstration of its causal role came later. Over roughly 30 years, interactions between clinicians and scientists helped move the field from empirical interferon treatment to discovery of the virus and the development of serological and virological tools for diagnosis and prognosis. The CDC’s 25-year timeline also notes that millions of Americans continue to live with the disease and that most do not know they are infected.
Improving HCV Detection: A Step-by-Step Approach
The study, conducted at San Giuseppe Hospital in Italy, compared the performance of two common anti-HCV assays: ARCHITECT® and VIDAS®. Researchers analyzed samples with low-positive results from the ARCHITECT® test using VIDAS® and a confirmatory immunoblot assay (INNO-LIA™) to determine the presence of anti-HCV antibodies.
- Initial Screening: Perform the first anti-HCV test using ARCHITECT®.
- Second-Level Screening: If the ARCHITECT® test is positive (with a signal-to-cutoff ratio between 1 and 8), conduct a second test using VIDAS®.
- Confirmatory Testing: Only samples that test positive on both ARCHITECT® and VIDAS® should undergo confirmatory anti-HCV immunoblot testing.
Where Testing Can Fall Short
Antibody testing has a window period: third-generation anti-HCV enzyme immunoassays typically require at least 5–6 weeks after acute infection for seroconversion to be detected, and seroconversion can be delayed for months or years in immunocompromised people. Antibody tests also cannot confirm whether infection is currently active. Even when the diagnostic algorithm seems straightforward, needing multiple tests and waiting for some results can impede efforts to reach hepatitis C elimination targets. CDC recommends screening all adults aged 18 and older and all pregnant women during each pregnancy, with more frequent testing for certain high-risk groups.
Key Takeaways: What This Means for You
The study highlights the importance of accurate and efficient HCV testing strategies. By implementing a two-step screening process that includes both ARCHITECT® and VIDAS®, healthcare providers can reduce the risk of false-positive results and ensure that individuals receive the appropriate diagnosis and care.
Evolving Laboratory Strategies
A systematic review and meta-analysis evaluates the diagnostic accuracy of HCV antigen testing. Its source summary describes HCV RNA detection as effective for identifying active infection, while noting its high cost and need for trained personnel. A 2021 review reports that highly sensitive molecular assays have replaced serological confirmatory assays, and that direct-acting antivirals have replaced interferon-based approaches. Together, these sources describe a laboratory landscape balancing diagnostic performance, access, and evolving methods.
Faster, More Accessible Detection
A 2024 review describes the current HCV diagnostic algorithm as slow and costly, while noting that the burden is highest among people with limited access to health care, including people who inject drugs and people in low- and middle-income countries. A 2025 review estimates that approximately 50 million people worldwide are infected and says many remain unaware because infection is often asymptomatic; it also notes that no vaccine is currently available. Future Market Insights projects the HCV testing market will grow from USD 0.9 billion in 2025 to USD 1.4 billion by 2035, a compound annual growth rate of 5.1%.
Different Results Across Assays
In a performance study of the automated VIDAS® anti-HCV immunoassay, positive antibody results were obtained in 61.4% of sera tested with VIDAS® and 41.4% tested with INNO-LIATM. The reported figures show that the proportion of positive results differed between the two assays in the tested sera. The snippet does not establish why the results differed or which assay was more accurate.
If you are undergoing HCV screening, it's important to discuss the testing process with your healthcare provider and understand the potential for false-positive results. Knowing that confirmatory testing is available can provide reassurance and help avoid unnecessary anxiety.
Ultimately, improved HCV detection methods contribute to better management of the virus, reducing the burden of liver disease and improving the health outcomes for millions of people worldwide. Stay informed and proactive about your health, and don't hesitate to ask questions about your HCV testing.